Lupus nephritis - alarmins may sound the alarm?

Arthritis Research and Therapy

Volumn 14, Issue 6, 2012, Pages

  Wu, Tianfu ^a   Mohan, Chandra ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; TOLL LIKE RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN;

EDITORIAL; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOGENESIS; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; URINE;

FEMALE; HMGB1 PROTEIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE;

EID: 84871701270     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4109     Document Type: Editorial

References (10)

1. Abdulahad DA, Westra J, Bijzet J, Dolff S, van Dijk MC, Limburg PC, Kallenberg CG, Bijl M. Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthritis Res Ther 2012, 14:R184. 10.1186/ar4015, 22892043.
2. Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M, Nyberg F. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 2005, 52:3639-3645. 10.1002/art.21398, 16255056.
3. Urbonaviciute V, Fürnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007, 81:67-74.
4. Zickert A, Palmblad K, Sundelin B, Chavan S, Tracey KJ, Bruchfeld A, Gunnarsson I. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther 2012, 14:R36. 10.1186/ar3747, 3392835, 22348591.
5. Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, Tracey KJ. High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 2008, 14:109-115. 10.1007/s00894-007-0256-x, 2258159, 18317568.
6. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007, 8:487-496.
7. Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes - implications for the immunopathogenesis of SLE. J Exp Med 2008, 205:3007-3018. 10.1084/jem.20081165, 2605236, 19064698.
8. D'Agati V, Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 2010, 6:352-360. 10.1038/nrneph.2010.54, 20421886.
9. Martens H, Nienhuis H, Gross S, der Steege GV, Brouwer E, Berden J, Sévaux RD, Derksen R, Voskuyl A, Berger S, Navis G, Nolte I, Kallenberg C, Bijl M. Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus 2012, 21:959-968. 10.1177/0961203312444495, 22513366.
10. Urbonaviciute V, Voll RE. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med 2011, 270:309-318. 10.1111/j.1365-2796.2011.02432.x, 21793951.